Enzymatic DNA Synthesis Market Size, Share & Trends Analysis Report By Service (Oligonucleotide Synthesis, Gene Synthesis), By Application (Synthetic Biology, Genetic Engineering), By End-use, By Region, And Segment Forecasts, 2024 - 2030

Enzymatic DNA Synthesis Market Size, Share & Trends Analysis Report By Service (Oligonucleotide Synthesis, Gene Synthesis), By Application (Synthetic Biology, Genetic Engineering), By End-use, By Region, And Segment Forecasts, 2024 - 2030

Enzymatic DNA Synthesis Market Growth & Trends

The global enzymatic DNA synthesis market is anticipated to reach USD 1.19 billion by 2030 and is expected to grow at a CAGR of 26.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Increasing biopharmaceutical research, advancements in DNA synthesis, and the expanding field of synthetic biology are expected to propel market growth. Moreover, the rising demand for precision medicine and therapeutics is further anticipated to propel the demand for the market over the forecast period.

The COVID-19 pandemic positively impacted the market, primarily by accelerating research & development in diagnostics, vaccines, and therapeutics. The demand for rapid and accurate genomic sequencing of the virus and the development of mRNA vaccines significantly boosted the demand for synthetic DNA. In addition, the pandemic emphasized the significance of quick, scalable, and precise DNA synthesis methods, leading to increased investment in enzymatic synthesis technologies. For instance, in July 2020, DNA Script secured USD 50 million in funding for its Series B round, raising the total investment to USD 89 million, propelling their synthetic DNA supply worldwide. These factors have impelled the market's growth and are anticipated to propel exponentially over the forecast period.

In addition, the rapid expansion of synthetic biology further propelled the demand for enzymatic DNA synthesis. This is attributed to the growing need for precise and efficient construction of complex genetic sequences used in engineering novel biological systems, such as synthetic organisms, therapeutic proteins, and bio-based materials. Furthermore, enzymatic DNA synthesis offers the speed, accuracy, and scalability required to meet the demands of synthetic biology, enabling researchers to innovate in areas like gene editing, metabolic engineering, and synthetic genomics. These factors are thus projected to impel the market's growth over the forecast period.

However, the high cost of producing and technical complexity of enzymatic DNA synthesis might limit their accessibility. These challenges can create barriers to widespread adoption, as the advanced equipment, specialized reagents, and expertise required for enzymatic synthesis contribute to higher operational costs. In addition, the complicated processes involved in ensuring the accuracy and scalability of synthesized DNA sequences may further complicate its use, potentially restricting its availability to only well-funded institutions and organizations with the necessary technical capabilities. Thereby hampering the growth of the market over the forecast period.

Enzymatic DNA Synthesis Market Report Highlights

• The oligonucleotide synthesis segment held the largest market share in 2023 due to its wide applications, such as genetic research, diagnostics, and therapeutic development. On the other hand, gene synthesis is anticipated to grow at the fastest CAGR over the forecast period
• In 2023, the synthetic biology segment is anticipated to dominate the market share for the application segment and is anticipated to grow at the fastest CAGR of 27.5%. This is attributed to the increasing application in gene editing, therapeutics, and industrial biotechnology
• Biopharmaceutical companies dominated the end use segment with the largest share in 2023 due to the growing demand for advanced therapeutic solutions, increased investment in R&D, and the adoption of cutting-edge biotechnologies for drug development and personalized medicine
• North America dominated the market with a share of 50.11% owing to factors such as strong R&D in biotechnology, medicine, and therapeutics, along with substantial government funding. Asia Pacific is anticipated to grow at the fastest CAGR over the forecast period.

Please note The report will be delivered in 2-3 business days upon order notification.